glp 1 inflammation reduction GLP-1 and Inflammation: How These Drugs Ease Arthritis Glucagon-like peptide-1 receptor: mechanisms and

Inclusion Criteria Exclusion Criteria Timeline for a Trial Participant Screening Participants are screened for eligibility to participate in the trial Treatment Participants receive weekly subcutaneous injections of either CagriSema or Tirzepatide, with a dose escalation period followed by maintenance dosing Follow-up Participants are monitored for safety and effectiveness after treatment What Are the Treatments Tested in This Trial

I'm not sure what word we want to use

Most initial visits at our Greenfield Hales Corners clinic take about 4560 minutes

These drugs come in various forms and strengths, and the doses usually change over the course of your treatment